REGN7508 Clinical Trials
6 recruitingDrug
Phase 35Phase 21
Showing 1–6 of 6 trials
Recruiting
Phase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
Regeneron Pharmaceuticals1,120 enrolled12 locationsNCT07410117
Recruiting
Phase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Regeneron Pharmaceuticals7,050 enrolled1 locationNCT07318610
Recruiting
Phase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Regeneron Pharmaceuticals1,200 enrolled45 locationsNCT07175428
Recruiting
Phase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Regeneron Pharmaceuticals2,000 enrolled16 locationsNCT07213778
Recruiting
Phase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Venous Thromboembolism (VTE)
Regeneron Pharmaceuticals2,000 enrolled44 locationsNCT07015905
Recruiting
Phase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Atrial Fibrillation (AF)
Regeneron Pharmaceuticals2,628 enrolled5 locationsNCT07430956